# Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

> **NCT06163820** · PHASE1,PHASE2 · RECRUITING · sponsor: **Melanoma and Skin Cancer Trials Limited** · enrollment: 46 (estimated)

## Conditions studied

- Melanoma Brain Metastases

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **RADIATION:** Hypofractionated stereotactic radiotherapy

## Key facts

- **NCT ID:** NCT06163820
- **Lead sponsor:** Melanoma and Skin Cancer Trials Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-31
- **Primary completion:** 2026-01-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06163820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06163820, "Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06163820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*